| This report contains COVID-19 specific updates.
Global Markets for Infectious Disease Treatments
Report Highlights
The global market for infectious disease treatments should grow from $72.4 billion in 2021 to $106.3 billion by 2026, at compound annual growth rate (CAGR) of 8.0% for the period of 2021-2026.
Report Includes
- 113 tables
- An updated review of the global markets for infectious disease treatments in the healthcare and pharmaceutical industry
- Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation and forecast the overall market size in dollar value terms, and corresponding market share analysis by disease type and geographic region
- Highlights of the market potential for infectious disease treatments, opportunities and gaps estimating current and future demand; and impact of COVID-19 on the progress of this market
- Emphasis on newer drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits, recently launched or in development
- Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
- Technology assessment of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated
- Insight into the competitive landscape featuring key mergers and acquisitions (M&A), collaboration agreements, and company revenue share analysis across the global infectious diseases market
- Review of key patent grants and new technologies with relate to innovations in infectious disease treatments
- Company profiles of the leading industry participants including Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis, and Roche
Report Scope
The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals, and diagnostic kits, recently launched or in development. Market share, market deterrents, unmet needs and other factors that drive research are also discussed, while patents that highlight research priorities and predict future trends are analyzed.
Specifically, outside the scope of research are vector/mosquito control approaches, strategies and products, drugs used for symptomatic treatment and not for the elimination of the virus from host, and details on suppliers of generics and non-branded generics. Also excluded are markets for hospital-based diagnosis that are not carried out by kits (for example, malaria slide smear-based tests), as well as discussion on the spread of vector-borne infection (such as malaria) via blood-transfusion.
BCC Research categorizes the markets based on regions defined by WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships for a large number of infectious diseases. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific.
Analyst Credentials
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
Report Highlights
The global market for infectious disease treatments totaled $64.8 billion in 2017. The market should total $99 billion by 2022, growing at a compound annual growth rate (CAGR) of 8.9% from 2017 to 2022.
Report Includes
- 84 data tables and 23 additional tables
- An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
- Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
- Examination of technological developments, future trends, and emerging opportunities
- Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by region
- Patent analyses
- Company profiles of major players in the market, including Alere (now Abbott), Novartis, Roche Diagnostics, Sanofi Pasteur and Siemens Healthineers
Report Highlights
The global market for infectious disease diagnostic, vaccine, and treatment products reached $108.4 billion in 2015. The market should reach $126.2 billion in 2016 and $183.2 billion in 2021, demonstrating a compound annual growth rate (CAGR) of 7.7% from 2016 to 2021.
Report Includes
- An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products.
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2021.
- Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans.
- Examination of technological developments, future trends, and emerging opportunities.
- Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region.
- A relevant patent analysis.
- Profiles of major players in the field of infectious disease treatments.
Report Highlights
The global market for infectious disease diagnostic, vaccine and pharmaceutical products was $59.2 billion in 2011 and $66.4 billion in 2012. Market growth looks promising, the overall market value for 2017 is projected to be $96.8 billion after increasing at a compound annual growth rate (CAGR) of 7.8%.
Report Includes
- An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
- Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
- Examination of technological developments, future trends, and emerging opportunities
- Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region
- Patent analysis
- Comprehensive company profiles of major players.
Report Highlights
-
The global market for infectious disease treatments was valued at $90.4 billion in 2009. This market is expected to increase at a compound annual growth rate (CAGR) of 8.8% to reach $138 billion in 2014.
-
The largest market share belongs to antibiotic treatments for bacterial and fungal diseases at 53% of the total infectious disease treatment market. Fungal disease treatments will experience a slightly higher compound annual growth rate (CAGR) of 6.2%, from $4.6 billion in 2009 to $6.2 billion in 2014.
-
Viral disease treatments will have the fastest compound annual growth rate (CAGR) of 12.1%, increasing from nearly $45 billion in 2009 to $79 billion in 2014.